# US 2021/0275693 A1 · Modified wound dressings

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275693 A1
- Document ID: US20210275693A1
- Status: Published application
- Kind: A1
- Application number: 17/201,898
- Filed: 2021-03-15
- Published: 2021-09-09
- Earliest claimed: 2016-03-30
- Assignees: Convatec Technologies In C.
- Applicants: Convatec Technologies In C.
- Inventors: Lucy Ballamy
- Web page: https://patentgrep.com/patent/US20210275693A1

## CPC

- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/0073: {semi-solid, gel, hydrogel, ointment}
- A61L 15/42: Use of materials characterised by their function or physical properties (liquid bandages A61L26/00)
- A61L 15/44: Medicaments
- A61L 15/56: Wetness-indicators or colourants
- A61L 15/60: Liquid-swellable gel-forming materials, e.g. super-absorbents
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61L 15/46: Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
- A61L 2300/406: Antibiotics
- A61L 2300/414: Growth factors
- A61L 2300/442: Colorants, dyes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Embodiments described herein relate to compounds for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. Further embodiments relate to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic conversion of specific substrates which are contained in the compositions. Additional embodiments relate to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

## Claims

### Claim 1

A wound dressing material comprising a compound of Formula I:
M-L-R Formula I
wherein:
M is a gel-forming polymer comprising 200 to 4000 monomeric units and is carboxymethylcellulose or cellulose or an oxidized cellulose or cellulose ethyl sulfonate;
R is a reporter molecule that includes a detectable label selected from the group consisting of a luminescent molecule, a chemiluminescent molecule, a fluorochrome, and a fluorescent quenching agent;
L is a linker that is either absent or present, and L, when present, connects M and R and comprises a neutral polymer which is an ethoxylated polyhydric alcohol, a polyvinyl pyrrolidone polymer, a polypropylene, a polyalkylene glycol, a polyamine or an ether, an amide, or an ester thereof; and
when L is absent, M and R are covalently connected.

### Claim 2 (depends on 1)

The wound dressing material of claim 1, wherein the L is absent.

### Claim 3 (depends on 1)

The wound dressing material of claim 1, wherein L is present.

### Claim 4 (depends on 1)

The wound dressing material of claim 1, wherein the reporter molecule comprises an enzyme substrate, wherein the enzyme substrate is a sugar, a polysaccharide, a nucleic acid, an amide, a peptide, a protein, a lipid, or a derivative thereof or a combination thereof.

### Claim 5 (depends on 1)

The wound dressing material of claim 1, wherein the gel-forming polymer is carboxymethylcellulose.

### Claim 6 (depends on 1)

The wound dressing material of claim 1, wherein the gel-forming polymer comprises about 500 to about 2000 monomeric units.

### Claim 7 (depends on 1)

The wound dressing material of claim 1, wherein the detectable label is fluorochrome.

### Claim 8 (depends on 7)

The wound dressing material of claim 7, wherein the reporter molecule comprises a fluorescent molecule selected from the group consisting of fluorescein, rhodamine, tetramethylrhodamine, R-phycoerythrin, Cy-3, Cy-5, Cy-7, Texas Red, Phar-Red, allophycocyanin (APC), fluorescein amine, eosin, dansyl, umbelliferone, 5-carboxyfluorescein (FAM), 2′7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), 6 carboxyrhodamine (R6G), N,N,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4′-dimethylaminophenylazo) benzoic acid (DABCYL), 5-(2′-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS), 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid, acridine, acridine isothiocyanate, r-amino-N-(3-vinylsulfonyl)phenylnaphthalimide-3,5, disulfonate (Lucifer Yellow VS), N-(4-anilino-1-naphthyl)maleimide, anthranilamide, Brilliant Yellow, coumarin, 7-amino-4-methylcoumarin, 7-amino-4-trifluoromethylcouluarin (Coumarin 151), cyanosine, 4′, 6-diaminidino-2-phenylindole (DAPI), 5′,5″-diaminidino-2-phenylindole (DAPI), 5′,5″-dibromopyrogallol-sulfonephthalein (Bromopyrogallol Red), 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin diethylenetriamine pentaacetate, 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid, 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC), eosin isothiocyanate, erythrosin B, erythrosin isothiocyanate, ethidium, 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), QFITC (XRITC), fluorescamine, IR144, IR1446, Malachite Green isothiocyanate, 4-methylumbelliferone, ortho cresolphthalein, nitrotyrosine, pararosaniline, Phenol Red, B-phycoerythrin, o-phthaldialdehyde, pyrene, pyrene butyrate, succinimidyl 1-pyrene butyrate, Reactive Red 4, lissamine rhodamine B sulfonyl chloride, rhodamine B, rhodamine 123, rhodamine X, sulforhodamine B, sulforhodamine 101, sulfonyl chloride derivative of sulforhodamine 101, tetramethyl rhodamine, riboflavin, rosolic acid, and terbium chelate derivatives.

### Claim 9 (depends on 7)

The wound dressing material of claim 7, wherein the reporter molecule comprises the detectable label and a quencher molecule.

### Claim 10 (depends on 7)

The wound dressing material of claim 7, wherein the reporter molecule or a portion thereof is released upon interaction with an enzyme.

### Claim 11 (depends on 7)

The wound dressing material of claim 7, wherein the reporter molecule comprises a substrate that is specific for a wound-specific enzyme.

### Claim 12 (depends on 11)

The wound dressing material of claim 11, wherein the wound-specific enzyme is a protease.

### Claim 13 (depends on 11)

The wound dressing material of claim 11, wherein the reporter molecule comprises a substrate that is specific for a wound-specific enzyme selected from the group consisting of MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stomelysin 1), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), human neutrophil elastase (HNE), cathepsin G, urokinase-type plasminogen activator (uPA), and lysozyme or any combination thereof.

### Claim 14 (depends on 1)

A method of diagnosing a status of a wound, comprising: contacting the wound with the wound dressing material of claim 1 to permit conversion of the reporter molecule into a detectable signal; and, detecting a signal.

### Claim 15 (depends on 14)

The method of claim 14, wherein conversion of the reporter molecule into the detectable signal is carried out by a wound-specific protease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the wound-specific protease is selected from the group consisting of MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stomelysin 1), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), human neutrophil elastase (HNE), cathepsin G, urokinase-type plasminogen activator (uPA), and lysozyme.

### Claim 17 (depends on 14)

The method of claim 14, further comprising determining a presence or absence of a chronic wound or an infected wound, wherein determining a presence or absence of a chronic wound or an infected wound comprises: measuring a parameter in the wound, comparing the measured parameter to a threshold level, and making a determination that the wound is chronic or infected if the level of the parameter in the wound is higher than the threshold level.

### Claim 18 (depends on 17)

The method of claim 17, wherein the parameter is an amount or activity of a wound-specific protease that is selected from the group consisting of MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stomelysin 1), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), human neutrophil elastase (HNE), cathepsin G, urokinase-type plasminogen activator (uPA), and lysozyme.

### Claim 19 (depends on 1, 14)

The method of claim 14, further comprising treating a chronic or an infected wound in a subject, comprising administering the wound dressing material of claim 1 topically or dermally to the wound.

### Claim 20

A wound dressing material selected from the group consisting of:
